Tumor Ablation Market Size (2024 - 2029)

Tumor Ablation Market Analysis

The Tumor Ablation Market size is estimated at USD 1.60 billion in 2024, and is expected to reach USD 2.60 billion by 2029, growing at a CAGR of 10.10% during the forecast period (2024-2029).

The tumor ablation market size is estimated at USD 1,622.4 million in 2024, and is expected to reach USD 2,631.0 million by 2029, growing at a CAGR of 10.15% during the forecast period (2024-2029).

The increasing burden of cancer, technological advancements in ablation devices, and growing demand of minimally invasive surgeries are the major drivers for the market.

Various cancer therapies such as ablation therapies are used as a treatment option for the management of several types of cancers, including metastatic disease. As cancer cases increase, the demand for advanced cancer therapy rises, which is expected to drive market growth over the forecast period. For instance, according to the American Cancer Society 2023 update, about 1.93 million new cancer cases were estimated to be reported in 2023 as compared to 1.9 million cases in 2022 in the United States. Thus, an increase in the burden of cancer is expected to augment the demand for ablation cancer therapies, thereby boosting market growth over the forecast period.

Similarly, an increase in breast cancer cases is expected to raise the demand for ablation therapies like laser ablation of breast tumors which is a United States Food and Drug Administration and Conformité Européenne approved procedure, thereby facilitating the market growth over the forecast period. For instance, in September 2023, the Government of Canada reported that about 28,600 Canadian women were diagnosed with breast cancer in 2022,i.e., 25% of all new cancer cases in women in 2022. 

Furthermore, multiple potential ablative technologies are being implemented to surmount the current limitations of thermal ablative technologies which are likely to facilitate the market growth over the forecast period. For instance, as per an article published in the Korean Journal of Radiology1 in June 2023, no-touch radiofrequency ablation has gained attention and has recently been implemented in local ablation therapy for hepatocellular carcinoma, as it provides improved local tumor control compared to conventional tumor-puncturing radiofrequency ablation. Thus, the adoption of new technologies is likely to bolster the market growth over the forecast period.

Moreover, robotics in interventional oncology can be of great help to reduce radiation exposure to operators and can increase procedure accuracy in the future. Robotics systems offering off-plane and multiplanar percutaneous intervention planning, targeting, as well as needle positioning, also using three-dimensional target views, are available for clinical use and can easily support practitioners.

The rising innovations and product launches by key market players over the forecast period are likely to boost the market growth. For instance, in April 2023, Compal Electronics, a Taiwanese electronics company, launched a new radiofrequency ablation (RFA) system for percutaneous, intraoperative coagulation and ablation of soft tissue, including partial or complete ablation of non-resectable liver lesions.

Therefore, due to the increase in cases of cancer and the rise in product launches coupled with technological advancements in tumour ablation devices, the studied market is expected to grow significantly during the study period. 

However, a strict regulatory process is expected to restrain the market's growth during the study period.

Tumor Ablation Industry Segmentation

Tumor ablation is an image-guided technique in which the cancer cells in the tumor are killed through the delivery of concentrated energy or chemicals; the energy or chemicals are delivered through probes/needles.The tumor ablation market is segmented by technology (radiofrequency ablation, microwave ablation, cryoablation, and other technologies), mode of treatment (surgical ablation, laparoscopic ablation, and percutaneous ablation), application (liver cancer, lung cancer, kidney cancer, bone metastasis, and other applications), and geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The market report also covers the estimated market sizes and trends for 17 countries across major regions globally.